T3	condition 75 89	cardiotoxicity
T4	total-participants 356 361	Forty
T5	control 517 530	control group
T6	intervention-participants 503 505	20
T7	control-participants 556 558	20
T14	outcome 1103 1107	LVEF
T15	outcome 1211 1226	LVEDD and LVESD
T16	outcome 1373 1377	LVEF
T20	outcome 1814 1857	rate of ST segment and T wave abnormalities
T21	cv-bin-percent 1862 1867	80.0%
T23	cv-bin-percent 1957 1962	25.0%
T25	cv-bin-percent 2013 2018	10.0%
T26	outcome 2019 2051	after two cycles of chemotherapy
T28	cv-bin-percent 2133 2138	55.0%
T29	cv-bin-percent 2140 2145	45.0%
T30	cv-bin-percent 2150 2156	45.0%,
T31	outcome 2330 2369	rate of abnormal expression of troponin
T32	cv-bin-percent 2374 2379	45.0%
T33	iv-bin-percent 2432 2437	10.0%
T34	iv-bin-percent 2252 2257	20.0%
T35	iv-bin-percent 2271 2276	10.0%
T36	iv-bin-percent 2294 2299	10.0%
T27	outcome 2082 2093	QRS voltage
T37	outcome 2095 2105	arrhythmia
T38	outcome 2110 2127	abnormal troponin
T1	intervention 22 67	low-dose carvedilol combined with candesartan
T2	cv-cont-mean 1384 1389	57.00
T43	cv-cont-sd 1392 1396	5.13
T8	cv-cont-mean 1404 1409	45.95
T44	cv-cont-sd 1412 1416	3.68
T39	iv-cont-mean 1490 1495	67.00
T45	iv-cont-sd 1498 1502	5.13
T40	iv-cont-mean 1510 1515	57.50
T46	iv-cont-sd 1518 1522	2.57
T41	cv-cont-mean 1634 1639	50.00
T47	cv-cont-sd 1642 1647	10.48
T42	cv-cont-mean 1657 1662	35.01
T48	cv-cont-sd 1665 1669	2.99
T9	outcome 1612 1617	LVEDD
T10	outcome 1622 1627	LVESD
T11	outcome 1330 1371	After four and six cycles of chemotherapy
T12	outcome 1578 1610	After six cycles of chemotherapy
T13	outcome 1889 1921	after six cycles of chemotherapy
T17	outcome 1963 1996	after four cycles of chemotherapy
